全球循環系統藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計心血管藥物市場將從 2025 年的 1,382.1 億美元成長到 2034 年的 1,953.6 億美元，2026 年至 2034 年的複合年成長率為 3.92%。

隨著心血管疾病在全球日益普遍，全球心血管藥物市場正顯著成長。心血管藥物用於治療高血壓、心臟衰竭、心律不整和冠狀動脈疾病等。這些藥物有助於調節血壓、改善心臟功能並降低嚴重併發症的風險。

多種因素正在推動心血管藥物市場的成長。人口老化、久坐的生活方式和不健康的飲食習慣導致心血管疾病發生率上升。藥物研發的進步正推動著治療心臟病的有效藥物的開發。

隨著醫療保健系統將重點轉向預防和長期治療策略，心血管藥物市場預計將持續成長。創新藥物療法和個人化醫療的持續研究將改善患者的治療效果。隨著人們對心臟健康的日益關注和醫療保健投資的不斷增加，對心血管藥物的需求預計將保持強勁。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球循環系統藥物市場：依藥物類別分類

• 市場分析、洞察與預測
• 抗高血壓藥物
• 血脂異常症藥物
• 抗凝血物
• 抗心律不整藥物
• 其他藥物分類

第5章 全球循環系統藥物市場：依適應症分類

• 市場分析、洞察與預測
• 高血壓
• 高血脂症
• 冠狀動脈疾病
• 心律不整
• 其他跡象

第6章 全球循環系統藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外
• 其他給藥途徑

第7章 全球循環系統藥物市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 網路藥房
• 零售藥房
• 其他分銷管道

第8章 全球循環系統藥物市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen
  • AstraZeneca
  • Baxter
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Lupin
  • Merck
  • Novartis
  • Pfizer

The Cardiovascular Drugs Market size is expected to reach USD 195.36 Billion in 2034 from USD 138.21 Billion (2025) growing at a CAGR of 3.92% during 2026-2034.

The global cardiovascular drugs market has grown significantly due to the increasing prevalence of heart-related diseases worldwide. Cardiovascular drugs are used to treat conditions such as hypertension, heart failure, arrhythmias, and coronary artery disease. These medications help regulate blood pressure, improve heart function, and reduce the risk of serious complications.

Several factors are driving the growth of the cardiovascular drugs market. Aging populations, sedentary lifestyles, and unhealthy dietary habits have contributed to a higher incidence of cardiovascular diseases. Advances in pharmaceutical research have led to the development of more effective medications for managing heart conditions.

In the future, the cardiovascular drugs market is expected to continue growing as healthcare systems focus on preventive and long-term treatment strategies. Ongoing research into innovative drug therapies and personalized medicine will improve patient outcomes. With rising awareness of heart health and increasing healthcare investments, demand for cardiovascular drugs will remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Antihypertensives
• Antihyperlipidemic
• Anticoagulants
• Antiarrhythmics
• Other Drug Classes

By Indication

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Arrhythmia
• Other Indications

By Route of Administration

• Oral
• Parenteral
• Other Routes of Administration

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

COMPANIES PROFILED

• Amgen, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, BristolMyers Squibb, Gilead Sciences, Johnson Johnson, Lupin, Merck, Novartis, Pfizer
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Antihypertensives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antihyperlipidemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anticoagulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antiarrhythmics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hyperlipidemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Coronary Artery Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Arrhythmia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Routes of Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Distribution Channels Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CARDIOVASCULAR DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CARDIOVASCULAR DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Amgen
  • 10.2.2 AstraZeneca
  • 10.2.3 Baxter
  • 10.2.4 Bayer
  • 10.2.5 Boehringer Ingelheim
  • 10.2.6 Bristol-Myers Squibb
  • 10.2.7 Gilead Sciences
  • 10.2.8 Johnson & Johnson
  • 10.2.9 Lupin
  • 10.2.10 Merck
  • 10.2.11 Novartis
  • 10.2.12 Pfizer